Rheumatoid Arthritis News

Researchers said they developed a comprehensive score that can identify patients at high risk for inflammatory arthritis, as well as a “simple score” that can identify patients at low risk, both of which “may be useful in clinical care.”

Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.

Individuals who live closer to the equator develop rheumatoid arthritis at a younger age, a link that is likely explained by socioeconomic status, according to data published in the Annals of the Rheumatic Diseases.

Patients with rheumatoid arthritis who demonstrate lower disease activity are more likely to remain in LDA or remission after switching from combination therapy to monotherapy, according to data published in the Journal of Rheumatology.

Peresolimab 700 mg is superior to placebo in the treatment of moderate-to-severe rheumatoid arthritis, according to data published in the New England Journal of Medicine.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

Patients with rheumatoid arthritis demonstrate a nearly 1.5-fold increased risk for developing Parkinson’s disease vs. those without RA, according to data published in JAMA Neurology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed concern level around COVID-19 in patients with RA at this stage of the pandemic, and whether or not patients with RA are urged to get fourth and fifth booster shots.